The Safety and Efficacy of Ruxolitinib in an Infant With Familial Hemophagocytic Syndrome Type 3: A Bridging Therapy Toward Hematopoietic Cell Transplantation and Treatment of Post‐Transplant Complications, Including Sinusoidal Obstruction Syndrome
The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Authors
- Yukayo Terashita (ORCID: https://orcid.org/0000-0003-1700-5337)
- Shunichiro Takezaki (ORCID: https://orcid.org/0000-0002-0425-4097)
- Masataka Hasegawa (ORCID: https://orcid.org/0000-0003-1037-1852)
- M. Ueki (ORCID: https://orcid.org/0000-0001-7379-4874)
- Atsushi Manabe (ORCID: https://orcid.org/0000-0002-6698-2348)
- Yuko Cho (ORCID: https://orcid.org/0000-0002-6238-6768)
- Shinsuke Hirabayashi (ORCID: https://orcid.org/0000-0001-7961-0968)
- Hiroki Ohata (ORCID: https://orcid.org/0000-0002-9940-9898)
- Kazuki Takahashi (ORCID: https://orcid.org/0000-0001-5924-1376)
Institutions
- Hokkaido University Hospital (JP)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1002/pbc.32073
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00